Key facts
- It has raised $7.6M across 1 recorded rounds; the latest was Early Stage VC ($7.6M) in Jun 2025.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for NBO Pharma
Funding rounds
1 roundsAbout NBO Pharma
Developer of an intranasal formulation of octreotide designed to treat idiopathic intracranial hypertension. The company offers a repurposed orphan drug using intranasal delivery that targets central nervous system receptors, enabling patients with idiopathic intracranial hypertension and their physicians to administer octreotide without injections and with lower systemic exposure.
- Sector
- Healthcare
- HQ
- Bedford, NY, United States
- Founded
- 2021
- Website
- nbopharma.com/
- Ownership
- Privately Held (backing)
NBO Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NBO Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NBO Pharma in its N-PORT filings yet. We sweep new filings monthly.